Malignant Bladder Neoplasm — Trials

Malignant Bladder Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

1,510 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 346
Recruiting: 177
Ph III recruiting: 23
Growth YoY: +17.9%
Industry share: 21%
Top sponsor: National Cancer Institute (NCI)
Termination share: 31.3%
Trials / 1,000 deaths: 20 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (179)

clinicaltrialsPublishedShowing 51–53 of 53 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01442519	Sequential Bacillus Calmette-Guérin (BCG) and Electromotive Mitomycin-C Versus Bacillus Calmette-Guérin (BCG) Alone for High Risk Superficial Bladder Cancer(BCG/EMDA-MMC)	completed	Phase 3	212	University of Rome Tor VergataOTHER	1	Sep 28, 2011	clinicaltrials
NCT00330707	Combined Use of BCG and Interferon Alpha in Bladder Cancer	completed	Phase 2 / Phase 3	140	National University Hospital, SingaporeOTHER	1	Mar 4, 2011